Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 10:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–27 of 3 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Parainfluenza Clear all

Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy Infants

NCT00308412

View directory record Official record

Conditions: Paramyxoviridae Infections, Virus Diseases
Interventions: rHPIV3cp45, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 36 Months

Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Source: ClinicalTrials.gov public record

Updated Jul 15, 2010 · Synced May 21, 2026, 10:53 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children

NCT01254175

View directory record Official record

Conditions: Parainfluenza Virus 3, Human
Interventions: rHPIV3cp45 Vaccine, Placebo Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 36 Months

Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 7
States / cities: Long Beach, California • San Diego, California • Chicago, Illinois + 3 more

Source: ClinicalTrials.gov public record

Updated Dec 2, 2014 · Synced May 21, 2026, 10:53 PM EDT

Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants

NCT00686075

View directory record Official record

Conditions: Healthy
Interventions: MEDI-534, Cohort 1, Placebo, Cohort 1, MEDI-534, Cohort 2, Placebo, Cohort 2, MEDI-534, Cohort 3, Placebo, Cohort 3, MEDI-534, Cohort 4, Placebo, Cohort 4, MEDI-534, Cohort 5, Placebo, Cohort 5; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 2 Months to 23 Months

Enrollment: 1,338 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 51
States / cities: Mobile, Alabama • Bentonville, Arkansas • Little Rock, Arkansas + 44 more

Source: ClinicalTrials.gov public record

Updated Sep 25, 2014 · Synced May 21, 2026, 10:53 PM EDT